| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL9a3 |
| Uniprot No | Q14050 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-684aa |
| 氨基酸序列 | QRVGL PGPPGPPGPP GKPGQDGIDG EAGPPGLPGP PGPKGAPGKP GKPGEAGLPG LPGVDGLTGR DGPPGPKGAP GERGSLGPPG PPGLGGKGLP GPPGEAGVSG PPGGIGLRGP PGPSGLPGLP GPPGPPGPPG HPGVLPEGAT DLQCPSICPP GPPGPPGMPG FKGPTGYKGE QGEVGKDGEK GDPGPPGPAG LPGSVGLQGP RGLRGLPGPL GPPGDRGPIG FRGPPGIPGA PGKAGDRGER GPEGFRGPKG DLGRPGPKGT PGVAGPSGEP GMPGKDGQNG VPGLDGQKGE AGRNGAPGEK GPNGLPGLPG RAGSKGEKGE RGRAGELGEA GPSGEPGVPG DAGMPGERGE AGHRGSAGAL GPQGPPGAPG VRGFQGQKGS MGDPGLPGPQ GLRGDVGDRG PGGAAGPKGD QGIAGSDGLP GDKGELGPSG LVGPKGESGS RGELGPKGTQ GPNGTSGVQG VPGPPGPLGL QGVPGVPGIT GKPGVPGKEA SEQRIRELCG GMISEQIAQL AAHLRKPLAP GSIGRPGPAG PPGPPGPPGS IGHPGARGPP GYRGPTGELG DPGPRGNQGD RGDKGAAGAG LDGPEGDQGP QGPQGVPGTS KDGQDGAPGE PGPPGDPGLP GAIGAQGTPG ICDTSACQGA VLGGVGEKSG SRSS |
| 预测分子量 | 63,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL9A3重组蛋白的3篇参考文献的简要概括(文献标题及作者为虚构示例，仅供格式参考)：
1. **"Recombinant Expression and Functional Analysis of COL9A3 in Cartilage Development"**
- 作者：Smith A, et al.
- 摘要：研究利用哺乳动物细胞系统成功表达重组COL9A3蛋白，证实其在软骨细胞外基质中的关键作用，揭示其通过调控胶原纤维网络影响软骨力学性能。
2. **"Structural Characterization of COL9A3 Mutants Linked to Osteoarthritis"**
- 作者：Lee J, et al.
- 摘要：通过昆虫细胞表达系统获得重组COL9A3蛋白及其致病突变体，分析突变导致蛋白结构异常，阐明其与骨关节炎发病机制的关联。
3. **"COL9A3 Recombinant Protein Production in Prokaryotic Systems: Challenges and Optimization"**
- 作者：Wang H, et al.
- 摘要：探索大肠杆菌中表达COL9A3重组蛋白的策略，优化折叠条件以克服原核系统对复杂胶原蛋白合成的限制，为后续功能研究提供高纯度蛋白。
4. **"Interaction Between COL9A3 and Extracellular Matrix Components Revealed by Recombinant Protein Assays"**
- 作者：Garcia R, et al.
- 摘要：利用重组COL9A3蛋白进行体外结合实验，发现其与II型胶原和硫酸软骨素的特异性相互作用，提示其在维持软骨基质稳定性中的双重功能。
(注：以上文献为模拟示例，实际研究需通过学术数据库检索具体论文。)
COL9A3 recombinant protein is derived from the alpha-3 chain of type IX collagen, a critical component of the extracellular matrix (ECM). Type IX collagen belongs to the fibril-associated collagens with interrupted triple helices (FACIT) family and plays a structural and regulatory role in tissues such as cartilage, vitreous humor, and intervertebral discs. The COL9A3 gene encodes the α3 chain, which combines with α1 and α2 chains (encoded by COL9A1 and COL9A2) to form heterotrimeric type IX collagen molecules. These molecules interact with type II collagen fibrils, stabilizing ECM architecture and mediating cell-matrix interactions through domains like the COL3 and NC4 globular domains.
Mutations in COL9A3 are linked to musculoskeletal disorders, including Stickler syndrome and multiple epiphyseal dysplasia (MED), characterized by joint pain, osteoarthritis, and skeletal abnormalities. Recombinant COL9A3 protein is engineered using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, bioactive forms for research and therapeutic development. It serves as a tool to study collagen assembly, ECM pathology, and disease mechanisms, particularly in cartilage degeneration. Additionally, it has potential applications in tissue engineering for cartilage repair and regenerative medicine. Challenges in production include maintaining proper post-translational modifications (e.g., hydroxylation) for functionality, often requiring optimized expression systems. Research on COL9A3 recombinant protein continues to advance understanding of collagen-related diseases and inform targeted therapies.
×
